-
Cantor Initiates Heron Therapeutics With Buy Rating, $41 Price Target
Tuesday, May 3, 2016 - 9:00am | 316Read More...Cantor Fitzgerald’s Chiara Russo mentioned that with Heron Therapeutics Inc (NASDAQ: HRTX)'s lead product, Sustol, coming up for FDA approval, there was potential for a differentiated label that would cover both delayed and acute CINV (Chemotherapy-Induced Nausea and Vomiting). The analyst...
-
Heron Therapeutics Falls 11%, Company Says FDA Has Not Concluded A Scheduled Review
Monday, February 29, 2016 - 11:14am | 176Read More...Heron Therapeutics Inc (NASDAQ: HRTX) announced on Monday that the U.S. Food and Drug Administration (FDA) has not taken any action on its New Drug Application (NDA) for SUSTOL. The FDA informed Heron Therapeutics that it has not yet concluded a review of the NDA despite a January 17, 2016,...
